Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer
© 2023. The Author(s), under exclusive licence to Springer Nature Limited..
BACKGROUND: We aimed to develop and validate a plasma extracellular vesicle circular RNA (circRNA)-based signature that can predict overall survival (OS) in first-line abiraterone therapy for metastatic castration-resistant prostate cancer (mCRPC) patients.
METHODS: In total, 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases. In the discovery phase, 30 plasma samples from 30 case-matched patients with or without early progression were obtained to generate circRNA expression profiles using RNA sequencing. In the training phase, differentially expressed circRNAs were examined using digital droplet PCR in a training cohort (n = 203). The circRNA signature was constructed using a least absolute shrinkage and selection operator Cox regression to predict OS. In the validation phase, the prognostic ability of this signature was prospectively validated in two external cohorts (Cohort I, n = 183; Cohort II, n = 166).
RESULTS: We developed a five-circRNA signature, based on circCEP112, circFAM13A, circBRWD1, circVPS13C and circMACROD2, which successfully stratified patients into high-risk and low-risk groups. The prognostic ability of this signature was prospectively validated in two external cohorts (P < 0.0001, P < 0.0001). Patients with high-risk scores had shorter OS than patients with low-risk scores.
CONCLUSION: This five-circRNA signature is a reliable predictor of OS for mCRPC patients undergoing abiraterone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
British journal of cancer - 128(2023), 7 vom: 22. März, Seite 1320-1332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tao, Wen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abiraterone |
|---|
| Anmerkungen: |
Date Completed 30.03.2023 Date Revised 27.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-023-02147-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352135581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352135581 | ||
| 003 | DE-627 | ||
| 005 | 20240127231827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-023-02147-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1272.xml |
| 035 | |a (DE-627)NLM352135581 | ||
| 035 | |a (NLM)36703078 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tao, Wen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2023 | ||
| 500 | |a Date Revised 27.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a BACKGROUND: We aimed to develop and validate a plasma extracellular vesicle circular RNA (circRNA)-based signature that can predict overall survival (OS) in first-line abiraterone therapy for metastatic castration-resistant prostate cancer (mCRPC) patients | ||
| 520 | |a METHODS: In total, 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases. In the discovery phase, 30 plasma samples from 30 case-matched patients with or without early progression were obtained to generate circRNA expression profiles using RNA sequencing. In the training phase, differentially expressed circRNAs were examined using digital droplet PCR in a training cohort (n = 203). The circRNA signature was constructed using a least absolute shrinkage and selection operator Cox regression to predict OS. In the validation phase, the prognostic ability of this signature was prospectively validated in two external cohorts (Cohort I, n = 183; Cohort II, n = 166) | ||
| 520 | |a RESULTS: We developed a five-circRNA signature, based on circCEP112, circFAM13A, circBRWD1, circVPS13C and circMACROD2, which successfully stratified patients into high-risk and low-risk groups. The prognostic ability of this signature was prospectively validated in two external cohorts (P < 0.0001, P < 0.0001). Patients with high-risk scores had shorter OS than patients with low-risk scores | ||
| 520 | |a CONCLUSION: This five-circRNA signature is a reliable predictor of OS for mCRPC patients undergoing abiraterone | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a abiraterone |2 NLM | |
| 650 | 7 | |a G819A456D0 |2 NLM | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 650 | 7 | |a Abiraterone Acetate |2 NLM | |
| 650 | 7 | |a EM5OCB9YJ6 |2 NLM | |
| 700 | 1 | |a Luo, Zi-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ya-Di |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bang-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Tao-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Wei-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ling-Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiu-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Zhan-Ao |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Liao-Yuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 128(2023), 7 vom: 22. März, Seite 1320-1332 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2023 |g number:7 |g day:22 |g month:03 |g pages:1320-1332 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-023-02147-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2023 |e 7 |b 22 |c 03 |h 1320-1332 | ||